Why the study?
GLP-1 receptor agonists are generally avoided in patients with a history of pancreatitis due to concerns about acute pancreatitis risk, leaving their role in managing severe hypertriglyceridemia underexplored.
Does GLP-1RA therapy prevent recurrent acute pancreatitis and reduce triglycerides in a patient with severe hypertriglyceridemia?
Does GLP-1RA therapy prevent recurrent acute pancreatitis and reduce triglycerides in a patient with severe hypertriglyceridemia?
GLP-1 receptor agonists may offer a safe and effective option for preventing recurrent hypertriglyceridemia-induced acute pancreatitis and achieving sustained triglyceride reduction in select high-risk patients.
May support GLP-1RA in select recurrent HTG-AP cases; leaves open prospective validation of safety and efficacy.
Glucagon-like peptide-1 receptor agonists (GLP-1RA) are generally avoided in patients with a history of pancreatitis due to concerns about potential associated risk of acute pancreatitis (AP). However, their role in managing severe hypertriglyceridemia (HTG) remains underexplored. We present a case of a 42-year-old woman with recurrent HTG-induced AP who was initiated on GLP-1RA and achieved 15% weight loss, sustained triglyceride reduction, and remained AP-free while on that therapy. This case highlights a potential new role for the use of GLP-1RAs for HTG-AP.
No takes yet. Share an insight, caveat, or question.
Guralwar et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: